RBC Capital Downgrades Sarepta Therapeutics to Sector Perform, Lowers Price Target to $142
Portfolio Pulse from Benzinga Newsdesk
RBC Capital has downgraded Sarepta Therapeutics from Outperform to Sector Perform and lowered its price target from $157 to $142.
May 28, 2024 | 10:13 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
RBC Capital has downgraded Sarepta Therapeutics from Outperform to Sector Perform and lowered its price target from $157 to $142.
The downgrade from Outperform to Sector Perform and the reduction in the price target from $157 to $142 by RBC Capital is likely to negatively impact investor sentiment and could lead to a short-term decline in SRPT's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100